REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Nootropic Focus

Cognitive Enhancementintermediate

84

synergy

84
Share
Peptides

2

Avg Daily mcg

1,000

Level

intermediate

Added

May 17, 2026

Overview

The Nootropic Focus stack combines two Russian-developed neuropeptides that operate through complementary mechanisms to enhance cognitive performance while reducing anxiety. Semax is a synthetic analog of ACTH(4-10) — the fragment of adrenocorticotropic hormone responsible for its cognitive effects without the adrenal-stimulating properties. Semax increases brain-derived neurotrophic factor (BDNF) expression by 3-4x in the hippocampus and prefrontal cortex, promotes nerve growth factor (NGF) synthesis, and modulates dopaminergic and serotonergic neurotransmission. In Russian clinical use since 1994, it is prescribed for cognitive impairment, stroke recovery, and optic nerve atrophy. Selank is a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin, with an additional Pro-Gly-Pro sequence that increases its stability and CNS penetration. Selank''s primary mechanism involves modulation of the GABAergic system — it acts as an anxiolytic without the sedation, cognitive impairment, or addiction potential of benzodiazepines. It also influences the expression of BDNF and enkephalins, creating a calm-but-focused mental state rather than the wired alertness of stimulants. The synergy between Semax and Selank is particularly elegant for cognitive enhancement: Semax provides the "drive" component — increased BDNF, enhanced dopaminergic tone, improved attention and working memory — while Selank provides the "calm" component — reduced anxiety, stabilized mood, and prevention of the stress response that impairs prefrontal function. Together they create a state of relaxed concentration ideal for demanding cognitive work. Both are administered nasally for direct access to the CNS via the olfactory epithelium, bypassing the blood-brain barrier. The nasal route provides onset within 5-15 minutes and duration of 4-6 hours.

Dosing Protocol

Semax

Every day· nasal

Read more about Semax →

600 mcg

per dose

Selank

Every day· nasal

Read more about Selank →

400 mcg

per dose

Goals & Evidence

FocusMemoryAnxiety reductionCognitive enhancementBDNF
Evidence tier:Human RCT

Warnings

  • Semax and Selank are approved medications in Russia. Not FDA-approved in US. Available as research peptides. Both have good safety profiles in clinical use.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.